The beneficial effect over 3 years by pictorial information to patients and their physician about subclinical atherosclerosis and cardiovascular risk: Results from the VIPVIZA randomized clinical trial-Reference-Cited by-同舟云学术

The beneficial effect over 3 years by pictorial information to patients and their physician about subclinical atherosclerosis and cardiovascular risk: Results from the VIPVIZA randomized clinical trial

Published:2021-09 Issue: Volume:7 Page:100199
ISSN:2666-6677
Container-title:American Journal of Preventive Cardiology
language:en
Short-container-title:American Journal of Preventive Cardiology

Author:

Bengtsson Anna,Norberg Margareta,Ng Nawi,Carlberg Bo,Grönlund Christer,Hultdin Johan,Lindahl Bernt,Lindahl Bertil,Nordin Steven,Nyman Emma,Wennberg Patrik,Wester Per,Näslund Ulf

Funder

Swedish Society of Medicine

Swedish Research Council

Heart and Lung Foundation

Region Västerbotten

Stroke-National Associated

Publisher

Elsevier BV

Reference33 articles.

1. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes;Kones;Vasc Health Risk Manag,2013

2. Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions

3. Impact of preclinical carotid atherosclerosis on global cardiovascular risk stratification and events in a 10-year follow-up: comparison between the algorithms of the Framingham Heart Study, the European SCORE and the Italian 'Progetto Cuore';Novo;J Cardiovasc Med,2019